Publication:
Clinical subtypes in breast cancer patients with brain metastases from an ambispective registry of advanced breast cancer, GEICAM/2014-03 (RegistEM)

Simple item page
dc.contributor.authorLópez Tarruella, Sara
dc.contributor.authorGuerrero-Zotano, Ángel
dc.contributor.authorAntolín, Silvia
dc.contributor.authorCruz, Josefina
dc.contributor.authorMartínez, Purificación
dc.contributor.authorRodríguez, César A.
dc.contributor.authorFalo, Catalina
dc.contributor.authorRodríguez Lescure, Álvaro
dc.contributor.authorAdrover, Encarna
dc.contributor.authorHernández, María
dc.contributor.authorAndrés, Raquel
dc.contributor.authorChacón, José Ignacio
dc.contributor.authorAlonso Romero, José Luis
dc.contributor.authorMiguel, Ana
dc.contributor.authorGómez Raposo, César
dc.contributor.authorMargelí, Mireia
dc.contributor.authorGonzález, Iria
dc.contributor.authorGuerra, José Antonio
dc.contributor.authorAntón, Antonio
dc.contributor.authorTibau, Ariadna
dc.contributor.authorMiralles, Juan José
dc.contributor.authorEscudero, María José
dc.contributor.authorBezares, Susana
dc.contributor.authorRojo, Federico
dc.contributor.authorÁlvarez, Isabel
dc.contributor.departmentMedicina Interna
dc.contributor.otherFacultades de la UMU::Facultad de Medicina
dc.date.accessioned2026-03-25T12:01:35Z
dc.date.available2026-03-25T12:01:35Z
dc.date.copyright© The AuthorS 2026.
dc.date.issued2026-02-20
dc.description.abstractBackground: Breast cancer frequently results in brain metastases (BCBM), leading to poor outcomes. Central nervous system (CNS) involvement entails significant challenges in advanced breast cancer (ABC) patients. Objectives: To characterize BCBM patients according to surrogate clinical BC subtypes and evaluate the interval between ABC and BCBM detection, both at ABC diagnosis (BCBM1 cohort) and for those who develop BCBM subsequently (BCBM2 cohort). Secondary objectives included analyzing the time-related outcomes by BC subtype. Design: RegistEM is an ongoing ambispective, observational study of ABC patients diagnosed since January/2016. Methods: We describe the characteristics of BCBM patients reported by January 22, 2024, categorized by BC subtype on the most recent tumor sample obtained before first-line therapy. Results: At the cutoff date, 346/1947 (18%) patients diagnosed with ABC between January/2016 and December/2019 developed BCBM, and 288/346 (83%) died. All patients were female, predominantly Caucasian (98%), with a median age of 55 years at ABC diagnosis. The distribution by subtype was 170/346 (49%) HR+/HER2−, 68/346 (20%) HR+/HER2+, 54/346 (16%) HR−/HER2+, and 51/346 (15%) HR−/HER2− (triple negative (TN)). One-fourth (85/346) were in the BCBM1 cohort, with 22/85 (26%) having BCBM as the only metastatic location; in this cohort, median time to BCBM was 38 months, with shorter intervals in HR−/HER2+ and TN subtypes (17 and 18 months, respectively). In the BCBM2 cohort (261/346), the median time to BCBM was 24 months, with the shortest interval in TN (13 months). Median survival from BCBM diagnosis was 26 months (95% confidence interval (CI), 20−35) in BCBM1 and 9 months (95% CI, 7−12) in BCBM2 (hazard ratio, 2.3; 95% CI, 1.7−3.0); TN subtype showed the poorest results (median of 6 months; 95% CI, 3−13). Conclusion: TN and HER2+ BC subtypes progressed faster to BCBM and had worse outcomes. Survival differed significantly between the two cohorts, BCBM1 and BCBM2. Continued research is essential to improve the treatment and prevention strategies.
dc.formatapplication/pdf
dc.format.extent22
dc.identifier.citationLópez-Tarruella, S., Guerrero-Zotano, Á., Antolín, S., Cruz, J., Martínez, P., Rodríguez, C. A., ... & Álvarez, I. (2026). Clinical subtypes in breast cancer patients with brain metastases from an ambispective registry of advanced breast cancer, GEICAM/2014-03 (RegistEM). Therapeutic Advances in Medical Oncology, 18, 17588359261421813.
dc.identifier.doihttps://doi.org/10.1177/17588359261421813
dc.identifier.eissn1758-8359
dc.identifier.issn1758-8340
dc.identifier.urihttp://hdl.handle.net/10201/222861
dc.languageeng
dc.relationThe authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: RegistEM was funded by Roche Farma, S.A.; Novartis Farmacéutica, S.A.; Celgene, S.L. (a BMS company); Pfizer, S.L.U.; AstraZeneca Farmacéutica Spain, S.A. in alliance with Daiichi Sankyo Spain, S.A.U.; Lilly, S.A.U.; Seagen, S.L.U.; Gilead Sciences, S.L.; and Stemline Therapeutics Switzerland GmbH, an affiliate of the A. Menarini Industrie Farmaceutiche Riunite S.r.L.
dc.relation.publisherversionhttps://journals.sagepub.com/doi/10.1177/17588359261421813
dc.rightsAttribution-NonCommercial 4.0 International*
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/*
dc.subjectBrain metastases
dc.subjectObservational study
dc.subjectReal-world evidence
dc.subjectRegistry
dc.subjectAdvanced breast cancer
dc.subject.odsObjetivo 3: Salud
dc.titleClinical subtypes in breast cancer patients with brain metastases from an ambispective registry of advanced breast cancer, GEICAM/2014-03 (RegistEM)
dc.typeinfo:eu-repo/semantics/article
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dspace.entity.typePublicationes
relation.isAuthorOfPublication79c9c691-9c36-4057-91b8-cf928d76847b
relation.isAuthorOfPublication.latestForDiscovery79c9c691-9c36-4057-91b8-cf928d76847b
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
lópez-tarruella-et-al-2026-clinical-subtypes-in-breast-cancer-patients-with-brain-metastases-from-an-ambispective.pdf
Size:
774.88 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.37 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Artículos